Developing an optimal approach to global drug safety

Journal of Internal Medicine

Volumn 250, Issue 4, 2001, Pages 271-279

  Balkrishnan, R ^a   Furberg, C D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

DISEASE SEVERITY; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FRANCE; HUMAN; IATROGENIC DISEASE; MASS MEDIUM; NEW ZEALAND; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SWEDEN; SYMPOSIUM; UNITED KINGDOM; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG APPROVAL; HUMANS; INTERNATIONAL COOPERATION; MEDICATION ERRORS; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; WORLD HEALTH;

EID: 0034787066     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00883.x     Document Type: Review

References (23)

1. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
2. The safety of newly approved medicines: Do recent market removals mean there is a problem?
3. The role of the clinical pharmacologist in the management of adverse drug reactions
4. The New Zealand intensive medicines monitoring programme in pro-active safety surveillance
5. Cardiovascular events in users of sildenafil: Results from first phase of prescription event monitoring in England
6. A new system for drug control in the EEC. Role of Sweden in an active monitoring of adverse effects
7. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems
8. How many deaths are due to medical errors?
9. Time to act on drug safety
10. Building knowledge of health care as a system
11. Medication error prevention: Profiling one of pharmacy's foremost advocacy efforts for advice on error prevention
12. Troglitazone-induced fulminant hepatic failure. Acute liver failure study group
13. The challenge of effectively communicating risk-benefit information
14. The accelerating need for pharmacovigilance
15. The safety of new medicines: The importance of asking the right questions
16. Database of patients' experiences (DIPEx): A multi-media approach to sharing experiences and information
17. International pharmacovigilance: Developing cooperation to meet the challenges of the 21st century
18. Reasons for reporting adverse drug reactions - Some thoughts based on an international review
19. The WHO international drug monitoring programme